Docetaxel cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK signal transduction pathway.
Navolanic
Patrick M
PM
Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, North Carolina 27858, USA.
Lee
John T
JT
McCubrey
James A
JA
D000972:Antineoplastic Agents, Phytogenic / Q000633:toxicity*; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology; D002070:Butadienes / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D000077143:Docetaxel; D004334:Drug Administration Schedule; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D009570:Nitriles / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000187:drug effects; D011518:Proto-Oncogene Proteins / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors*; D015398:Signal Transduction; D043823:Taxoids / Q000633:toxicity*; D013997:Time Factors
D000972:Antineoplastic Agents, Phytogenic; D002070:Butadienes; D004791:Enzyme Inhibitors; D009570:Nitriles; D011518:Proto-Oncogene Proteins; D043823:Taxoids; C113580:U 0126; D000077143:Docetaxel; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D019908:Proto-Oncogene Proteins c-raf; D020928:Mitogen-Activated Protein Kinases